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Abstract 
Background  
Pregnancy-associated cancer is associated with maternal morbidities and adverse pregnancy 
outcomes, and is reporting to be increasing. Hospital discharge data have the potential to provide 
timely information on cancer incidence, which is central to evaluation and improvement of clinical 
care for women. This study aimed to assess the accuracy and reliability of hospital data for identifying 
incident pregnancy-associated cancers compared with incident cancers from an Australian population-
based statutory cancer registry. 
Methods  
Birth data from 2001–2008, comprised 470,277 women with 679,736 maternities, were linked to 
cancer registry and hospitalisation records to identify newly diagnosed cancers during pregnancy or 
within 12 months of delivery. Two hospital-identified cancer groups were examined; “all cancer 
hospitalisations”, which replicates a scenario where identification of individuals is not possible and 
hospitalisations are used as the unit of analysis, and “index cancer hospitalisation” (first cancer 
admission per woman per pregnancy). 
Results  
The incidence of pregnancy-associated cancer (according to cancer registry) was 145.4/100,000 
maternities. Incidence of cancer was over- and under- estimated in “all cancer hospitalisations” and 
“index cancer hospitalisation” by 73.9% and 22.1% respectively. Overall, the sensitivity of “index 
cancer hospitalisation” was 60.4%, positive predictive value (PPV) 77.7%, specificity and negative 
predictive value both 100%. Melanoma ascertainment was only 36.1% and breast cancer 62.9%. For 
other common cancers sensitivities ranged from 72.1% to 78.6% and PPVs 56.4% to 87.3%. 
Conclusion  
Although hospital data provide another source of cancer identification, the ascertainment and 
accuracy are insufficient to obtain reliable cancer incidence estimates for the obstetric population.  
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Background 
Cancers associated with pregnancy are reported to be increasing, and this has been attributed to 
increasing maternal age and women’s interaction with health services during pregnancy [1]. Women 
with cancer diagnosed during pregnancy or within 12 months of delivery are at increased risk of 
maternal morbidities and adverse pregnancy outcomes [1]. Current information on incidence of cancer 
associated with pregnancy is central to evaluation and improvement of clinical care for women. 
 
Population-based statutory cancer registries are a reliable source for identifying incident cancers in 
populations [2-4]. However, the extensive quality assurance processes implemented by cancer 
registries can delay the timely availability of cancer data [5]. Consequently, there is increasing interest 
in the use of routinely collected and easily accessible administrative data, such as hospital discharge 
data, for identifying incident cancers and assessing health service utilisation and quality of care for 
cancer patients [2-4,6]. One disadvantage of using databases of hospitalisation records is that 
individuals with multiple hospitalisations cannot be identified. For example, several obstetric research 
studies in the United States (US) to date have relied solely on hospitalisation records, which means 
100 records may come from 100 individuals or 10 individuals each admitted 10 times [7-9]. Further 
complications arise in determining pregnancy-associated cancers due to inability in identifying the 
duration of pregnancy in weeks of gestation, resulting in an imprecise pregnancy exposure period [7].  
 
The quality of estimates of hospital-ascertained cancer incidence relies on complete and accurate 
ascertainment of recorded diagnoses. However, the validity and completeness of hospital data for 
identifying incident cancers associated with pregnancy have yet to be established. Several US studies 
have validated Medicaid or Medicare claims data (inpatient, outpatient and physician claims) for 
identification of incident cancers with cancer registries as the “gold standard”, with sensitivities 
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ranging from 68% to 97% and positive predictive values ranging from 83% to 96% [10-15].  There 
have also been limited efforts to link private insurer claims to cancer registries, with focus on cancer 
treatment information [16]. The generalisability of such findings to specific populations (e.g., 
obstetric populations) remains questionable, given that the majority of studies are among elderly 
populations. Therefore the aim of this study was to determine the accuracy and reliability of hospital 
diagnoses for identification of incident pregnancy-associated cancers, both overall and by cancer type, 
compared with incident diagnoses from a population-based statutory cancer registry. 
 
Methods 
Data sources and study population 
The study population comprised 470,277 women who gave birth in New South Wales (NSW) in the 
period 2001 to 2008, which corresponded to 679,736 maternities. NSW is the most populous state of 
Australia with a resident population of approximately 7 million people. Approximately one-third of 
all Australian births occur in NSW public or private hospitals. 
 
Data were obtained from three linked NSW population databases: the Perinatal Data Collection 
(PDC), Admitted Patient Data Collection (APDC) and Central Cancer Registry (CCR). The PDC is a 
statutory surveillance system that includes births of at least 20 weeks gestation or at least 400 grams 
birth weight. The APDC (referred to as “hospital data”) is a census of all inpatient hospitalisations to 
NSW public and private hospitals. The CCR (referred to as “registry data”) is a statutory case-based 
registry of all newly diagnosed cancers in NSW since 1972 with the exception of non-melanoma skin 
cancers. Cancer diagnoses in the CCR are coded according to the 3rd edition of the International 
Classification of Diseases for Oncology [17]. The registry data are validated by a rigorous procedure 
to ensure the completeness and quality of data are high. Over 90% of cancers are verified by 
pathology and are confirmed as the primary cancer diagnosis. Less than 1% of cancers are ascertained 
from the death certificate [18]. Based on treatment categories, cancers were categorised into 13 
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clinical groupings [18]. For validation purposes, we used the registry data as the ‘gold standard’ of 
identification of incident cancers associated with pregnancy. 
 
PDC birth records from 2001 to 2008 were linked to the cancer registry and hospitalisation records to 
identify newly diagnosed cancers during pregnancy or within 12 months of delivery (referred to as 
‘pregnancy-associated cancer’) [1,19]. Linkage to the PDC birth data allowed accurate identification 
of the duration of pregnancy in completed weeks of gestation for each woman who gave birth. Record 
linkage of the three databases was carried out by the NSW Centre for Health Record Linkage using 
probabilistic record linkage methods [20,21]. This involves a process of blocking and matching 
combinations of selected variables with identifying information such as name, date of birth, address 
and hospital. Each match was assigned with a probability weight [22]. The probabilistic record 
linkage for this study is highly reliable with less than three in 1,000 false positive links and less than 
five in 1,000 missed links [20]. The researchers were provided anonymised data. The study was 
approved by the NSW population and Health Services Research Ethics Committee. 
 
For identification of pregnancy-associated cancers from hospital data we searched up to 22 diagnosis 
fields associated with each pregnancy and postpartum hospital admission for cancer diagnoses. The 
diagnosis fields were coded according to the ICD-10-AM coded (10th  revision of the International 
Classification of Disease, Australian Modification ) with cancer diagnoses indicated by codes of  
C00–C96 [23]. As our aim was to identify incident cancers, any hospitalisation record coded as 
secondary, in-situ or benign cancer was excluded from the analysis. Hospital-identified pregnancy-
associated cancers were examined based on two groups: i) ‘all cancer hospitalisations’, refers to the 
total number of hospitalisations with a cancer diagnosis and women could have multiple 
hospitalisations during pregnancy.This replicates a scenario where identification of individuals is not 
possible and hospitalisations (records) are used as the unit of analysis and; ii) “index cancer 
hospitalisation”, identified by taking the record with the earliest admission date for each cancer type. 
The latter replicates a scenario where individuals can be identified in the hospital data and the first 
record is considered to be an incident cancer.  
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Statistical analysis 
The incidence estimated from ‘all cancer hospitalisations’ and the ‘index cancer hospitalisation’ were 
compared with the incidence estimated from registry data (both overall and by cancer type). The 
percentage differences of the numbers of incident pregnancy-associated cancers between registry data 
and hospital data were calculated. To assess the accuracy and reliability of the hospital identification 
of incident pregnancy-associated cancers only ‘index cancer hospitalisation’ data were compared with 
registry data. The following reporting characteristics with 95% exact binomial confidence interval 
(95%CI) were computed: sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV). Sensitivity (sometimes referred to as true positive fraction) is the proportion 
of maternities with an associated cancer, as ascertained by the registry gold standard, that were also 
identified in the hospital data, thus measuring completeness of identification.  Specificity (equivalent 
to one minus false positive fraction) is the proportion of maternities without an associated cancer that 
were also not identified in the hospital data.  PPV is the proportion of maternities with an associated 
cancer identified in the hospital data that in fact had an associated cancer, denoting accuracy. NPV is 
the proportion of maternities without an associated cancer identified in the hospital data that in fact 
did not have an associated cancer. We examined the false-positive and false-negative pregnancy-
associated cancers in the hospital data (compared with registry data) to determine if some of these 
were prevalent cancers or had an inconsistent cancer type. To differentiate truly incident from false-
positive cancers, we compared the hospital-identified cancers with registry data from 1994 onwards 
and regarded those previously notified cancers of the same type as prevalent cancers. Analysis was 
carried out in SAS, Version 9.2 (SAS Institute, Cary NC, USA) [24].  
 
Results 
 Incidence of pregnancy-associated cancer from registry and hospital data 
Between 2001 and 2008, a total of 988 pregnancy-associated cancers were identified from the registry 
data, corresponding to an overall crude incidence of 145.4 per 100,000 maternities (Table 1). The 
number and resultant incidence estimates of hospital-identified pregnancy-associated cancer were 
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notably higher among “all cancer hospitalisations” (252.7 per 100,000 maternities) and lower among 
the “index cancer hospitalisation” (113.3 per 100,000 maternities) (Table 1). Breast and 
lymphohaematopoeitic cancers resulted in large number of hospitalisations. The most common cancer 
in the registry data was melanoma with an incidence of 47.4 per 100,000 maternities, which was 
55.9% higher than that reported in the “index cancer hospitalisation” (20.9 per 100,000 maternities). 
The next most common cancers were breast (32.1 per 100,000 maternities in registry data) and thyroid 
and other endocrine cancers (19.6 per 100,000 maternities), and these rates were also comparatively 
higher than that reported in the “index cancer hospitalisation” (22.4 and 17.5 per 100,000 maternities 
respectively) (Table 1). 
 
Reporting characteristics of pregnancy-associated cancer 
As the majority of women did not have a cancer associated with pregnancy, the specificities and 
negative predictive values of all cancers were close to 100%. Overall the sensitivity of hospital record 
identification of cancer was 60.4% and PPV was 77.7% (Table 2). The sensitivities for the majority of 
pregnancy-associated cancers were over 70.0%, except for melanoma (36.1%), breast (62.9%), 
colorectal (64.3%) and head and neck cancers (69.2%) (Table 2). Respiratory and urogenital cancers 
had 100% sensitivities, although their sample sizes were small. There was some variation in positive 
predictive values by cancer type. Breast, thyroid and other endocrine, gynaecological, neurological 
and head and neck cancers had PPVs ranging from 81.8% to 87.3%. For the remaining cancers, PPV 
ranged from 56.4% for lymphohaematopoeitic cancer to 79.9% for melanoma (Table 2). 
 
Investigation of false-positive and false-negative pregnancy-associated cancers 
Compared with registry data, there were 166 false-positive and 380 false-negative pregnancy-
associated cancers among “index cancer hospitalisation” (Table 2). False-positive cancers were 
predominately lymphohaematopoeitic cancer (56.4%, n = 48) and false-negative cancers were 
predominately melanoma (53.7%, n = 204) (Table 2). Of the 166 false positives, registry data 
indicated that 86 (51.8%) were prevalent cancers and 22 (13.3%) were inaccurate/inconsistent 
identification of the cancer type. The cancers that were most frequently misclassified in the hospital 
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data were colorectal cancer (n = 7, misclassified as upper gastrointestinal cancer), followed by 
melanoma (n = 3, misclassified as breast or bone and other connective tissue cancers) and 
gynecological cancer (n = 4, misclassified as upper gastrointestinal cancer). False-positive prevalent 
cancers were primarily lymphohaematopoeitic (38 out of 86, 44.2%), melanoma (13, 15.1%), breast 
(14, 16.3%) and thyroid and other endocrine cancers (10, 11.6%). 
 
Discussion 
This record linkage-based validation study determined the accuracy of ICD-10-AM hospital diagnoses 
in estimating the incidence of pregnancy-associated cancer. We have demonstrated that using 
hospitalisations as the unit of analysis, rather than the individual, substantially over-estimated the 
incidence of pregnancy-associated cancer. In contrast, among individual-level hospital data the overall 
incidence was under-estimated by 22.1%. Specifically, the incidence of melanoma and breast cancer 
was under-estimated by 55.9% and 30.3% respectively. Pregnancy-associated melanoma was 
frequently missed in the hospital data, and was the major contributor to the false negatives. Other 
common cancers (breast, thyroid, gynaecological and lymphohaematopoeitic cancers) achieved only 
moderate levels of ascertainment (72.1–78.6%) and accuracy (56.4–87.3%). 
 
There is no literature based on obstetric populations available for direct comparison of our reporting 
characteristics. Published studies have predominately assessed the use of Medicare claims data 
compared with medical records or cancer registries for ascertainment of selected cancers (mainly 
breast cancer) with varying sensitivities and positive predictive values, depending on the definitions 
used, the study timeframe and identification algorithms (first diagnostic code only, all diagnostic 
codes or a combination of diagnostic or surgical procedure codes) [10-15]. Studies using ICD-9 coded 
hospital discharge data to identify incident breast, colorectal and lung cancers with cancer registries as 
the “gold standard” achieved better reporting characteristics than in our obstetric population [2,15,25]. 
For example, for breast cancer the sensitivity was 77–85% PPV 57–91%, colorectal cancer: sensitivity 
72% PPV 60–88% and lung cancer: sensitivity 81% PPV 59–79%. A study comparing ICD-10 coded 
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diagnoses in hospital discharge data with medical records as the “gold standard” reported a much 
greater ascertainment and accuracy (breast cancer: sensitivity 96% PPV 94%, colon cancer: sensitivity 
93% PPV 96% and lung cancer: sensitivity 97% PPV 94%) than we report using ICD-10 for an 
obstetric population [26]. This is likely due to an older, non-specific hospitalised study population, 
which in general has a different pattern of hospital activity from an obstetric population. In NSW 
between 2001 and 2008, about 16% women with singleton pregnancy and 64% women with multifetal 
pregnancies were admitted to hospital at least once during 20–36 gestation weeks [27,28].  
 
The evaluation of false-positive and false-negative pregnancy-associated cancers was insightful in 
considering the poorer identification of cancer from the hospital records of pregnant women. In 
accordance with literature, the common reasons for false positives were prevalent cancers or 
misclassification of cancer type [3]. Unfortunately, we were unable to evaluate the underlying causes 
of false-negative cancers. Others have speculated that the false-negative (missed) cancers may be due 
to coding errors, cancers notified from death certificate or other non hospital-based institutions [3]. In 
our obstetric population we believe outpatient cancer management (e.g., for melanoma) to be an 
important reason for false negatives. Furthermore, cancer may not be the reason for hospitalisation of 
a pregnant woman and diagnoses that are not relevant to the current admission are not required to be 
coded [29]. 
 
The strength of our study is the use of ICD-10 for coding hospital diagnoses. ICD-10 codes, based on 
surgical speciality, allow more detailed diagnoses coding than ICD-9 codes [30]. Importantly, there is 
a complete registration of cancers in the NSW statutory data collection, which provided the gold 
standard of identification of incident pregnancy-associated cancers without the need of an 
independent validation source. The linkage to cancer registry dating back to 1994 provided a unique 
opportunity to assess extensive history of cancer for identification of prevalent cancers, and to 
mitigate their impact on the positive predictive values [3,4]. Unlike other studies which focused on 
specific cancers, our comparison of reporting characteristics was done overall and by cancer type, and 
accounted for women with multiple primary cancers in a pregnancy. However, we were unable to 
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perform comparison by stratifying age or stage of cancer because of the limited sample size. Several 
limitations of our study also deserve consideration. The hospital data represent only inpatient stays; it 
may be less complete in capturing cancers where outpatient diagnosis and treatment are more 
common, e.g., melanoma. However, the data also provide a general representation of inpatient stays 
regardless of age or insurance status [15], and they are more assessable than the primary health 
utilisation data. Finally, as the reporting characteristics are sensitive to the sample size, careful 
interpretation is needed for cancers with small sample sizes. 
 
Conclusion 
The timely availability of population level data is a key factor in surveillance [31]. In 2012, NSW 
cancer registry data were available for linkage to the end of 2008, while hospital data were available 
through June 2011 [20]. Unfortunately, we do not consider the ascertainment and accuracy of 
pregnancy-associated cancers as determined by our hospital data of sufficient to be relied on for 
contemporary cancer incidence estimates. 
 
Our study shows that the use of hospital data for identifying incident pregnancy-associated cancers 
achieved only moderate levels of ascertainment and accuracy. Although hospital data may provide 
another source of cancer identification for a cancer registry there will still need to be rigorous 
assurance to confirm cancers in order to obtain reliable estimates of incidence. 
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Table 1. Pregnancy-associated cancer rates in the registry and hospital discharge datasets 
 Clinical group of cancer Incidence of pregnancy-associated cancer by data source   
 
Cancer Registera 
 
All hospitalisationsb 
 
Index hospitalisationb 
 N % Rate   N % Rate %diff   N % Rate %diff 
Melanoma 322 33 47.4  168 9.8 24.7 -47.8  142 18 20.9 -55.9 
Breast 218 22 32.1  491 29 72.2 125.2  152 20 22.4 -30.3 
Thyroid and other endocrine 133 14 19.6  198 12 29.1 48.9  119 16 17.5 -10.5 
Gynaecological 94 9.5 13.8  161 9.4 23.7 71.3  81 11 11.9 -13.8 
Lymphohaematopoeitic 87 8.8 12.8  340 20 50 290.8  110 14 16.2 26.4 
Colorectal 35 3.5 5.1  44 2.6 6.5 25.7  22 2.9 3.2 -37.1 
Neurological 22 2.2 3.2  57 3.3 8.4 159.1  24 3.1 3.5 9.1 
Bone and other connective tissue 19 1.9 2.8  64 3.7 9.4 236.8  25 3.2 3.7 31.6 
Head and Neck 14 1.4 2.1  13 0.8 1.9 -7.1  11 1.4 1.6 -21.4 
Upper Gastrointestinal 18 1.8 2.6  124 7.2 18.2 588.9  52 6.8 7.7 188.9 
Respiratory 7 0.7 1  17 1 2.5 142.9  9 1.2 1.3 28.6 
Ill-defined and unknown primary sites 11 1.1 1.6  22 1.3 3.2 100  12 1.6 1.8 9.1 
Urogenital 8 0.8 1.2  19 1.1 2.8 137.5  11 1.4 1.6 37.5 
Any 988 100 145    1,718 100 253 73.9   770 100 113 -22.1 
Rates are expressed per 100,000 pregnancies. 
%diff , percentage difference of the number of incident pregnancy-associated cancers between registry and hospital data. 
aTwo women had multiple cancer notifications of different type in a pregnancy. 
bTwenty-three women had multiple cancer hospitalisations of different type in a pregnancy. 
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Table 2. Reporting characteristics of incident pregnancy-associated cancer identified in hospital data compared with cancer registry data  
Clinical group of cancer Reporting characteristics of pregnancy-associated cancer 
TP (N) Sn (%) 95% CI (%) FP (N) PPV (%) 95% CI (%) FN (N) 
Melanoma  115 36.1 [30.8,41.6] 29 79.9 [72.4,86.1] 204 
Breast 134 62.9 [56.0,69.4] 20 87.0 [80.7,91.9] 79 
Thyroid and other endocrine 103 78.6 [70.6,85.3] 15 87.3 [79.9,92.7] 28 
Gynaecological 70 77.8 [67.8,85.9] 15 82.4 [72.6,89.8] 20 
Lymphohaematopoeitic 62 72.1 [61.4,81.2] 48 56.4 [46.6,65.8] 24 
Colorectal 18 64.3 [44.1,81.4] 11 62.1 [42.3,79.3] 10 
Neurological 20 90.9 [70.8,98.9] 4 83.3 [62.6,95.3] 2 
Bone and other connective tissue 16 88.9 [65.3,98.6] 7 69.6 [47.1,86.8] 2 
Head and Neck 9 69.2 [38.6,90.9] 2 81.8 [48.2,97.7] 4 
Upper Gastrointestinal 15 83.3 [58.6,96.4] 5 75.0 [50.9,91.3] 3 
Respiratory 6 100 [54.1,100 ] 3 66.7 [29.9,92.5] 0 
Ill-defined and unknown primary sites 4 50.0 [15.7,84.3] 4 50.0 [15.7,84.3] 4 
Urogenital 8 100 [63.1,100 ] 3 72.7 [39.0,94.0] 0 
Any 580 60.4 [57.2,63.5] 166 77.7 [74.6,80.7] 380 
TP: True positive; Sn: Sensitivity; TN: True negative; Sp: Specificity; FP: False positive; PPV: Positive  
predictive value; FN: False negative NPV: Negative predictive value. 
Note: The specificities and negative predictive values of all cancers were close to 100%. 
 
